How frequently and how soon should we screen our patients for the presence of antimalarial retinopathy? [4]

Arthritis and Rheumatism

Volumn 46, Issue 2, 2002, Pages 561-

  Alarcón, Graciela S ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE;

ADULT; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; FEMALE; HUMAN; LETTER; PRIORITY JOURNAL; RETINOPATHY; RHEUMATOID ARTHRITIS; SCREENING TEST; SYSTEMIC LUPUS ERYTHEMATOSUS; VISUAL IMPAIRMENT;

EID: 0036166317     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10054     Document Type: Letter

References (10)

1. Guidelines for monitoring drug therapy in rheumatoid arthritis
2. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice
3. Detection and prevention of maculopathy associated with antimalarial agents
4. Hydroxychloroquine retinopathy: Is screening necessary?
5. Hydroxychloroquine retinopathy despite regular ophthalmologic evaluation: A consecutive series
6. Retinal toxicity in long term hydroxychloroquine treatment
7. Hydroxychloroquine toxicity despite normal dose therapy
8. Long-term course of antimalarial maculopathy after cessation of treatment
9. Ophthalmologic considerations in using antimalarials in the United States
10. Ophthalmologic safety profile of antimalarial drugs